TickerFacts.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$4.05M
Year ended 2025-12-31
$1.78M
Trailing 12 months to 2026-06-30
+57.0%
3-year compound annual growth
2021-12-31: $1.02M2022-12-31: $1.05M2023-12-31: $3.52M2024-12-31: $3.62M2025-12-31: $4.05M$4.05M
2021-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$4.05M+12.0%2026-03-31, From 2025-01-01
2024-12-31$3.62M+2.9%2026-03-31, From 2024-01-01
2023-12-31$3.52M+235.8%2025-02-26, From 2023-01-01
2022-12-31$1.05Mn/c2024-09-04, From 2022-01-01
2021-12-31$1.02Mn/a2023-03-15, From 2021-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)2025-12-31$4.05M+12.0%
Traws Pharma, Inc. (TRAW)2025-12-31$12.14M-5.5%
Longeveron Inc. (LGVN)2025-12-31$12.04M+48.0%
Genprex, Inc. (GNPX)2025-12-31$9.43M-10.5%
Oragenics Inc (OGEN)2025-12-31$2.39M-41.8%
Medicus Pharma Ltd. (MDCX)2025-12-31$7.72M+118.9%
Korsana Biosciences, Inc. (KRSA)2025-12-31$959.0K+235.3%
Lantern Pharma Inc. (LTRN)2025-12-31$11.51M-28.6%
Decoy Therapeutics Inc. (DCOY)2025-12-31$368.2K-52.2%

Compare SHPH, TRAW, LGVN, GNPX side by side · Screen every company in Pharmaceutical Preparations ↗